HomeCompareICPT vs EPRT

ICPT vs EPRT: Dividend Comparison 2026

ICPT yields 10.53% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $23.3K in total portfolio value· pulled ahead in Year 7
10 years
ICPT
ICPT
● Live price
10.53%
Share price
$19.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.1K
Annual income
$2,037.15
Full ICPT calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ICPT vs EPRT

📍 EPRT pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ICPT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPT
Annual income on $10K today (after 15% tax)
$894.74/yr
After 10yr DRIP, annual income (after tax)
$1,731.58/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,183.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPT + EPRT for your $10,000?

ICPT: 50%EPRT: 50%
100% EPRT50/50100% ICPT
Portfolio after 10yr
$51.7K
Annual income
$7,438.93/yr
Blended yield
14.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ICPT
Analyst Ratings
16
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$22.11
+16.4% upside vs current
Range: $10.00 — $44.00
Altman Z
-5.0
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPT buys
0
EPRT buys
0
No recent congressional trades found for ICPT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPTEPRT
Forward yield10.53%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$40.1K$63.4K
Annual income after 10y$2,037.15$12,840.73
Total dividends collected$15.4K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$22.11$35.50

Year-by-year: ICPT vs EPRT ($10,000, DRIP)

YearICPT PortfolioICPT Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,753$1,052.63$11,205$505.18+$548.00ICPT
2$13,732$1,156.19$12,672$682.46+$1.1KICPT
3$15,955$1,262.49$14,490$930.48+$1.5KICPT
4$18,443$1,370.97$16,786$1,282.69+$1.7KICPT
5$21,215$1,481.06$19,753$1,791.56+$1.5KICPT
6$24,292$1,592.22$23,677$2,541.64+$615.00ICPT
7← crossover$27,697$1,703.90$29,008$3,672.99$1.3KEPRT
8$31,451$1,815.59$36,463$5,425.08$5.0KEPRT
9$35,580$1,926.82$47,238$8,221.57$11.7KEPRT
10$40,107$2,037.15$63,385$12,840.73$23.3KEPRT

ICPT vs EPRT: Complete Analysis 2026

ICPTStock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Full ICPT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ICPT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPT vs SCHDICPT vs JEPIICPT vs OICPT vs KOICPT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.